Lameness Repair Company

President John Lai Discusses Current Auditing State, the New Kush Product and the Company’s New Additions

President John Lai Discusses Current Auditing State, the New Kush Product and the Company’s New Additions

GlobeNewswire•September 28, 2017
Minneapolis, MN., Sept. 28, 2017 (GLOBE NEWSWIRE) — John Lai, President of PetVivo Holdings Inc. (OTCPink:PETV) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. In the beginning of the interview, Mr. Lai discusses the important addition of CEO Wes Hayne and how the auditing process of the company financials is coming to a close. Mr. Lai later discusses the new CFO and how Cindy Jenkins brings the proper controls with her to bring PetVivo current and how she will be able to keep it current with future filings. Mr. Lai also briefly discusses the new Kush commercial launch and later in the interview talks about when the revenues will hit the income statement after launch of this product. Furthermore, Mr. Lai highlights the addition of two outside independent directors to the company and elaborates on the experienced back ground that these two individuals will be bringing to PetVivo.
In closing, President John Lai states, “We feel we have put the right team together to execute and move this company forward for quite a period of time to manage the growth that we anticipate with the launch of commercial products that is disruptive to the industry of how you treat osteoarthritis.”
To listen to the full interview please click here or the following link:

Featured Interview: President & Chairman John Lai of PetVivo Holdings Inc. (OTCPink: PETV)

About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes, and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking Commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Source: Uptick Newswire

Press Release PetVivo Adds Two Independent Board Members

Press Release PetVivo Adds Two Independent Board Members

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 9-19-2017

PRESS RELEASE

 

PetVivo Adds David Deming and Peter Vezmar as Independent Directors

 

PetVivo Holdings, Inc. (www.petvivo.com) is pleased to announce that David Deming and Peter Vezmar will join the PetVivo PetVivo Board of Directors as independent members.

 

Peter Vezmar is currently the President and CEO of Marula Enterprises, a holding company founded to pursue investment opportunities primarily focused on targeted middle-market companies. Peter has more than thirty-five years of diverse experience in business management and strategy, corporate finance, IPOs, mergers and acquisitions, financial reporting, regulatory compliance, tax matters and corporate governance. Including a wide range of experience and understanding in many industries, including options/futures, life sciences/biotech, IT technologies, insurance, recycling, transportation/logistics, advertising, renewable energy and micro-brewery, among others.

“I look forward to joining the PetVivo team and working hard to realize the potential value of its innovative technology for shareholders,” commented Peter Vezmar.

David Deming has over thirty years of experience in client service, sales, marketing, operations and compliance.

David currently is a Partner at Asymmetric Capital Management, LLC. and he also serves as the Acting CEO, Treasurer and a Director at Wildfire 5G, Inc. Asymmetric Capital Management provides investment management services and the company is a pioneer in the build out of Hedged Beta Indices. Wildfire, 5G designs, builds, maintains, and operates next generation protected internet wireless networks that deliver a host of high-speed internet and telecommunication services to residential, educational, medical, hospitality and enterprise industries.

 

“I am very excited to be joining the Petvivo Board as they are a leading-edge growth company.  I look forward to working with their experienced, innovative senior management team,” stated David Deming.

 

“We are very pleased to have these two gentlemen join our Board of Directors. Both David and Peter have extensive experience operating and solving the problems that high growth businesses face. They add another level of expertise to our team,” noted Wes Hayne, the Company’s CEO.

 

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

8-K – Current report

Filed: 2017-09-19 AccNo: 0001477932-17-004579 Size: 65 KB
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits
Source: Petvivo SEC

Press Release New Hire Cynthia Jenkins

Press Release New Hire Cynthia Jenkins

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Wednesday, 8-30-2017

FOR IMMEDIAGE RELEASE

 

PETVIVO HOLDINGS, INC. ENGAGES Cynthia Jenkins AS CHIEF FINANCIAL OFFICER

 

PetVivo Holdings, Inc. (www.petvivo.com) is pleased to announce that Cynthia Jenkins will join the PetVivo team as the Company’s Chief Financial Officer (CFO). For more than forty years Ms. Jenkins has specialized in facilitating startup companies to build solid foundations in their financial and compliance/regulations departments.  She has extensive expertise in finance, accounting and treasury functions in addition to regulatory compliance and audit expertise.

 

“I am excited to have Cindy Jenkins join our team. Cindy has the experience that is difficult to find,” noted Wes Hayne, the Company’s CEO, “Her work ethic to hit deadlines is unparalleled and necessary in a growth company with a constant change in dynamics.”

 

Over her career, Ms. Jenkins has held the offices of CEO, President, Vice President, CFO, and Secretary/Treasurer and has been in upper management of small to mid-size broker-dealers and early stage companies.  She has extensive financial, compliance, and operational experience to facilitate new and existing firms grow and acclimate to the rules and regulations of the SEC and FINRA. She also specializes in AML audits, 3012 GAP Analysis testing, and documenting companies’ Written Supervisory and Compliance Procedures.  She holds Series 7, 24, 27, 52, 63, and 99 securities licenses.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

Real Time Web Analytics